Literature DB >> 11286710

Structured treatment interruptions to control HIV-1 and limit drug exposure.

L J Montaner1.   

Abstract

Although therapy-mediated suppression of HIV-1 is effective and results in a degree of immune reconstitution, the complications resulting from life-long treatment emphasize the need for alternatives. This review discusses the use of structured interruptions in antiviral therapy to induce drug-free periods of immune-mediated control of HIV-1. Such an approach has the ultimate objective of harnessing anti-viral immune responses, reducing drug exposure (toxicity and cost) and potentially extending the clinical benefits of a suppressive treatment regimen.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11286710     DOI： 10.1016/s1471-4906(00)01809-3

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  10 in total

1.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T cells in infected children correlate positively with plasma viral load.

Authors:  Florence Buseyne; Daniel Scott-Algara; Françoise Porrot; Béatrice Corre; Nassima Bellal; Marianne Burgard; Christine Rouzioux; Stéphane Blanche; Yves Rivière
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

4.  Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Maxwell Pistilli; Aidan Hancock; Griffin Reynolds; Cecile Gallo; Joe Ondercin; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

5.  Treatment of Primary HIV.

Authors:  Joanne Stekler; Ann Collier
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.663

6.  CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

Authors:  Jennifer Serwanga; Susan Mugaba; Auma Betty; Edward Pimego; Sarah Walker; Paula Munderi; Charles Gilks; Frances Gotch; Heiner Grosskurth; Pontiano Kaleebu
Journal:  AIDS Res Treat       Date:  2011-01-18

7.  Nonlinear observer output-feedback MPC treatment scheduling for HIV.

Authors:  Ryan Zurakowski
Journal:  Biomed Eng Online       Date:  2011-05-27       Impact factor: 2.819

8.  Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Authors:  Emmanouil Papasavvas; Jay R Kostman; Karam Mounzer; Robert M Grant; Robert Gross; Cele Gallo; Livio Azzoni; Andrea Foulkes; Brian Thiel; Maxwell Pistilli; Agnieszka Mackiewicz; Jane Shull; Luis J Montaner
Journal:  PLoS Med       Date:  2004-12-28       Impact factor: 11.069

9.  Reconsidering early HIV treatment and supervised treatment interruptions.

Authors:  Richard A Koup
Journal:  PLoS Med       Date:  2004-11-30       Impact factor: 11.069

10.  In Silico Modeling in Infectious Disease.

Authors:  Silvia Daun; Gilles Clermont
Journal:  Drug Discov Today Dis Models       Date:  2007-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.